Ildong Pharmaceutical Co., Ltd. (249420.KS)
KRW 11350.0
(-5.42%)
KRW 11350.0
(-5.42%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -53.41 Billion KRW | 27.16% |
| 2022 | -73.33 Billion KRW | -34.85% |
| 2021 | -54.37 Billion KRW | -919.86% |
| 2020 | 6.63 Billion KRW | 628.32% |
| 2019 | -1.25 Billion KRW | -104.43% |
| 2018 | 28.34 Billion KRW | 11.76% |
| 2017 | 25.36 Billion KRW | 71.45% |
| 2016 | 14.79 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 547.88 Million KRW | 416.45% |
| 2024 Q3 | 3.6 Billion KRW | 557.8% |
| 2024 Q1 | 106.08 Million KRW | 103.71% |
| 2023 Q2 | -19.18 Billion KRW | -29.29% |
| 2023 Q3 | -17.04 Billion KRW | 11.13% |
| 2023 Q4 | -2.86 Billion KRW | 83.21% |
| 2023 FY | -53.41 Billion KRW | 27.16% |
| 2023 Q1 | -14.83 Billion KRW | 35.79% |
| 2022 Q4 | -23.1 Billion KRW | -23.28% |
| 2022 Q3 | -18.74 Billion KRW | 15.55% |
| 2022 Q2 | -22.19 Billion KRW | -138.96% |
| 2022 Q1 | -9.28 Billion KRW | 49.76% |
| 2022 FY | -73.33 Billion KRW | -34.85% |
| 2021 Q4 | -18.48 Billion KRW | -23.74% |
| 2021 Q2 | -8.42 Billion KRW | 38.41% |
| 2021 Q3 | -14.93 Billion KRW | -77.27% |
| 2021 FY | -54.37 Billion KRW | -919.86% |
| 2021 Q1 | -13.68 Billion KRW | -140.89% |
| 2020 FY | 6.63 Billion KRW | 628.32% |
| 2020 Q4 | -5.68 Billion KRW | -196.95% |
| 2020 Q3 | 5.85 Billion KRW | -21.84% |
| 2020 Q1 | -1.04 Billion KRW | 94.17% |
| 2020 Q2 | 7.49 Billion KRW | 819.23% |
| 2019 FY | -1.25 Billion KRW | -104.43% |
| 2019 Q2 | 8.34 Billion KRW | 3.44% |
| 2019 Q3 | 87.7 Million KRW | -98.95% |
| 2019 Q4 | -17.88 Billion KRW | -20490.05% |
| 2019 Q1 | 8.07 Billion KRW | -18.55% |
| 2018 Q4 | 9.91 Billion KRW | 145.27% |
| 2018 Q1 | 6.73 Billion KRW | 24.1% |
| 2018 Q2 | 7.65 Billion KRW | 13.56% |
| 2018 FY | 28.34 Billion KRW | 11.76% |
| 2018 Q3 | 4.04 Billion KRW | -47.21% |
| 2017 Q3 | 10.97 Billion KRW | 83.37% |
| 2017 Q2 | 5.98 Billion KRW | 101.97% |
| 2017 FY | 25.36 Billion KRW | 71.45% |
| 2017 Q4 | 5.43 Billion KRW | -50.53% |
| 2017 Q1 | 2.96 Billion KRW | -71.58% |
| 2016 Q4 | 10.42 Billion KRW | 139.08% |
| 2016 FY | 14.79 Billion KRW | 0.0% |
| 2016 Q3 | 4.36 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | 14753.536% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 169.48% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 32.86% |
| HANDOK Inc. | 12.57 Billion KRW | 524.662% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | -2585.457% |
| Yuhan Corporation | 74.56 Billion KRW | 171.641% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | 577.862% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | -196.065% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 123.753% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | 1847.923% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 472.237% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | 9056.627% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | 5642.592% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | 297.613% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | 14753.536% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | -588.721% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | 1424.305% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 23.635% |
| JW Holdings Corporation | 143.66 Billion KRW | 137.182% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 121.662% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 153.256% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | -12.713% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | 871.158% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | 925.488% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | 711.788% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | 14753.536% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 209.535% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 140.041% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 153.256% |
| Yuhan Corporation | 74.56 Billion KRW | 171.641% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | 355.34% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | 1813.533% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 224.241% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 153.256% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | 360.773% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 197.212% |
| CKD Bio Corp. | -20.15 Billion KRW | -165.066% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 265.724% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | 311.119% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 264.235% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | -12.713% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 261.154% |
| Boryung Corporation | 68.26 Billion KRW | 178.248% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | -42.459% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 472.237% |
| JW Lifescience Corporation | 32.09 Billion KRW | 266.454% |